IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-7.62%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$297M
AUM Growth
+$297M
(-9.6%)
Cap. Flow
-$15.4M
Cap. Flow
% of AUM
-5.17%
Top 10 Holdings %
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$8.41M |
| 2 |
uniQure
QURE
|
$8.23M |
| 3 |
Biogen
BIIB
|
$7.51M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$7.34M |
| 5 |
Gilead Sciences
GILD
|
$6.67M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$14.9M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$11.8M |
| 3 |
Amgen
AMGN
|
$10.2M |
| 4 |
Harmony Biosciences
HRMY
|
$8.39M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$7.93M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $21.3M | 7.17% | 79,246 -38,000 | -32% | -$10.2M |
|
2
Incyte
INCY
$16.5B
| $20.7M | 6.97% | 358,454 | – | – |
|
|
3
Gilead Sciences
GILD
$140B
| $17.5M | 5.9% | 233,584 +89,000 | +62% | +$6.67M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.5M | 5.57% | 317,856 +141,000 | +80% | +$7.34M |
|
|
5
BioMarin Pharmaceuticals
BMRN
$11.2B
| $13.6M | 4.58% | 153,656 +95,000 | +162% | +$8.41M |
|
6
Supernus Pharmaceuticals
SUPN
$2.53B
| $11.8M | 3.96% | 426,500 -97,000 | -19% | -$2.67M |
|
7
Vera Therapeutics
VERA
$1.38B
| $10.4M | 3.5% | 758,355 -216,872 | -22% | -$2.97M |
|
|
8
Biogen
BIIB
$19.4B
| $10.3M | 3.48% | 40,200 +29,200 | +265% | +$7.51M |
|
|
9
Harmony Biosciences
HRMY
$2.12B
| $10.3M | 3.47% | 314,500 -256,000 | -45% | -$8.39M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.4M | 3.17% | 216,000 -44,000 | -17% | -$1.92M |
|
11
Ultragenyx Pharmaceutical
RARE
$2.89B
| $8.91M | 3% | 250,052 +170,000 | +212% | +$6.06M |
|
|
12
uniQure
QURE
$896M
| $8.33M | 2.81% | 1,241,500 +1,226,000 | +7,910% | +$8.23M |
|
13
Aurinia Pharmaceuticals
AUPH
$1.58B
| $8.07M | 2.72% | 1,040,530 +467,000 | +81% | +$3.62M |
|
14
United Therapeutics
UTHR
$13.8B
| $7.66M | 2.58% | 33,959 -18,800 | -36% | -$4.24M |
|
15
Vertex Pharmaceuticals
VRTX
$100B
| $7.3M | 2.46% | 21,000 | – | – |
|
|
16
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.28M | 2.45% | 8,847 -18,153 | -67% | -$14.9M |
|
17
Illumina
ILMN
$15.8B
| $6.93M | 2.34% | 50,500 | – | – |
|
|
18
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.52M | 2.2% | 36,800 -44,800 | -55% | -$7.93M |
|
19
Amylyx Pharmaceuticals
AMLX
$836M
| $5.4M | 1.82% | 295,000 +270,000 | +1,080% | +$4.94M |
|
20
Krystal Biotech
KRYS
$4.27B
| $5.34M | 1.8% | 46,092 +147 | +0.3% | +$17K |
|
|
KRTX
21
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.16M | 1.74% | 30,500 +4,800 | +19% | +$812K |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $4.07M | 1.37% | 58,300 | – | – |
|
23
Erasca
ERAS
$445M
| $3.79M | 1.28% | 1,926,000 +500,000 | +35% | +$985K |
|
24
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.74M | 1.26% | 179,702 +28,702 | +19% | +$597K |
|
|
RVNC
25
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.31M | 1.11% | 288,726 | – | – |
|